Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Qiagen ( (QGEN) ) has shared an update.
QIAGEN N.V. announced a manager’s transaction involving Toralf Haag, a member of the supervisory body, related to a synthetic share repurchase initiative. Approved in June 2024 and enacted in January 2025, this transaction saw every 36 issued QIAGEN shares consolidated into 35, impacting the number of shares held by Mr. Haag, which decreased by 73 shares to 2,551 common shares. This move is part of QIAGEN’s strategic financial management to optimize shareholder value.
More about Qiagen
QIAGEN N.V. operates in the biotechnology industry, focusing on providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. They are known for their products in the areas of nucleic acid purification, genetic testing, and bioinformatics.
YTD Price Performance: -0.02%
Average Trading Volume: 949,621
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $9.69B
Find detailed analytics on QGEN stock on TipRanks’ Stock Analysis page.
